Page 18 - ANTIFUNGAL SUSCEPTIBILITY OF CLINICAL YEAST ISOLATES 2018-2020

4. Candida glabrata complex (C. glabrata complex)

A total of 167 C. glabrata complex were analyzed from various type of

clinical specimens. The isolates were mainly from blood (141, 84.4%), followed by
body fluid (5, 3.0%), tissue (3, 1.8%), perineum (2, 1.2%), pericardial fluid (2, 1.2%),

and 1 each (0.6%) from urine, pus and pleural fluid samples (Table 4.1). The MIC

ranges,MIC50 and MIC90 of seven (7) antifungals are shown in Table 4.2.

Table 4.1: Distribution of C. glabrata complex isolated based on clinical specimens
in 2018-2020.
Specimen Type Number
Blood 141 (84.4%)
Body fluid 5 (3.0%)
Tissue 3 (1.8%)
Perineum 2 (1.2%)
Pericardial fluid 2 (1.2%)
Urine 1 (0.6%)
Pus 1 (0.6%)
Pleural fluid 1 (0.6%)
Others 11 (6.6%)
Total 167

Table 4.2: MIC50, MIC90 and MIC range values (µg/mL) for C. glabrata in 2018-2020.
Antifungals MIC50 MIC90 MIC Range

Amphotericin B 0.5 1 0.03 - 25

Fluconazole 6 16 0.38 - 256

Itraconazole 1.5 6 0.032 - 32

Posaconazole * * 0.5 - 4

Voriconazole 0.125 0.5 0.008 - 32

Anidulafungin 0.023 0.064 0.001 - 32

Caspofungin 0.5 0.75 0.03 - 32

Micafungin 0.015 0.06 0.003 - 12

5-Fluorocytosine * * 0.003 - 1

*The number of isolates tested were very low.

18 |